Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Piperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 2/20 | 0.33 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.33 |
| ▸ | RGS12 | O14924 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.30 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperazine SCHEMBL5700791 | 0.93 | HIF1A (0.43) | HIF1AMAPTPDE4AKDRCXCR4 | |
| Piperazine SCHEMBL29088716 | 0.93 | HIF1A (0.43) | HIF1AMAPTPDE4AKDRCXCR4 | |
| Phosphoramidic Acid SCHEMBL5035761 | 0.89 | — | — | |
| Phosphoramidic Acid SCHEMBL5035760 | 0.89 | HIF1A (0.36) | HIF1AMAPTPDE4AKDRANPEP | |
| Piperazine SCHEMBL23235242 | 0.85 | HIF1A (0.50) | HIF1AMAPTPDE4AKDRCXCR4 | |
| Piperazine SCHEMBL2783137 | 0.85 | HIF1A (0.50) | HIF1AMAPTPDE4AKDRCXCR4 | |
| Piperazine SCHEMBL28128235 | 0.85 | HIF1A (0.50) | HIF1AMAPTPDE4AKDRCXCR4 | |
| Piperazine SCHEMBL27815540 | 0.85 | HIF1A (0.50) | HIF1AMAPTPDE4AKDRCXCR4 | |
| Piperazine SCHEMBL5053500 | 0.85 | HIF1A (0.50) | HIF1AMAPTPDE4AKDRCXCR4 | |
| Piperazine SCHEMBL227947 | 0.85 | HIF1A (0.50) | HIF1AMAPTPDE4AKDRCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025076126-A1 | AGENTS THAT BIND NUCLEIC ACIDS ENCODING ELAVL3 CRYPTIC EXONS, PHARMACEUTICAL COMPOSITIONS, AND USES IN MANAGING NEUROLOGICAL DISEASES | EMORY UNIVERSITY (US) | 2025-04-10 | — | — | WO | claimed |
| US-20240279660-A1 | Methods and Compositions for Managing Vascular Conditions Using miR-483 Mimics and HIF1alpha Pathway Inhibitors | UNIV EMORY (US) | 2024-08-22 | — | — | US | claimed |
| US-11976279-B2 | Methods and compositions for managing vascular conditions using miR-483 mimics and HIF1alpha pathway inhibitors | EMORY UNIVERSITY (US) | 2024-05-07 | — | — | US | claimed |
| US-20220090079-A1 | Methods and Compositions for Managing Vascular Conditions Using miR-483 Mimics and HIF1alpha Pathway Inhibitors | UNIV EMORY (US) | 2022-03-24 | — | — | US | claimed |
| US-11149274-B2 | Methods and compositions for managing vascular conditions | EMORY UNIVERSITY (US) | 2021-10-19 | — | — | US | claimed |
| US-20200095583-A1 | Methods and Compositions for Managing Vascular Conditions | UNIV EMORY (US) | 2020-03-26 | — | — | US | claimed |
| US-20190112603-A1 | Methods and Compositions for Managing Vascular Conditions Using miR-483 Mimics and HIF1alpha Pathway Inhibitors | UNIV EMORY (US) | 2019-04-18 | — | — | US | claimed |
| US-20180362984-A1 | Methods and Compositions for Managing Vascular Conditions | UNIV EMORY (US) | 2018-12-20 | — | — | US | claimed |
| US-9932585-B2 | Manipulating microRNA for the management of neurological diseases or conditions and compositions related thereto | EMORY UNIVERSITY (US) | 2018-04-03 | — | — | US | claimed |
| US-20170051284-A1 | Manipulating MicroRNA for the Management of Neurological Diseases or Conditions and Compositions Related Thereto | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-02-23 | — | — | US | claimed |
| US-9458458-B2 | Manipulating microRNA for the management of neurological diseases or conditions and compositions related thereto | EMORY UNIVERSITY (US) | 2016-10-04 | — | — | US | claimed |
| US-20160002628-A1 | METHODS AND COMPOSITIONS FOR MANAGING VASCULAR CONDITIONS | EMORY UNIVERSITY | 2016-01-07 | — | — | US | claimed |
| US-20150133522-A1 | MANIPULATING MICRORNA FOR THE MANAGEMENT OF NEUROLOGICAL DISEASES OR CONDITIONS AND COMPOSITIONS RELATED THERETO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-05-14 | — | — | US | claimed |
| US-20140309280-A1 | ASSAYS FOR MICRO-RNA-182 AS A BIOMARKER FOR MUSCLE ATROPHY AND THERAPEUTIC APPLICATIONS | EMORY UNIVERSITY (US) | 2014-10-16 | — | — | US | claimed |
| US-20260098863-A1 | Tension-Activated Cell Tagging (TaCT) | UNIV EMORY (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260092918-A1 | Molecular Tension Probes and Methods to Determine or Monitor the Efficacy of Cancer and Other Immune Therapies | UNIV EMORY (US) | 2026-04-02 | — | — | US | disclosed |
| US-20250339539-A1 | Phosphate Membrane Nanodiscs Conjugated to Therapeutic Agents and Medical Uses Thereof | UNIV EMORY (US) | 2025-11-06 | — | — | US | disclosed |
| US-20140335606-A1 | PURIFICATION OF STEM CELL-DERIVED CARDIOMYOCYTES USING MOLECULAR BEACONS TARGETING CARDIOMYOCYTE SPECIFIC mRNA | GEORGIA TECH RESEARCH CORPORATION | 2014-11-13 | — | — | US | disclosed |
| US-20140309280-A1 | ASSAYS FOR MICRO-RNA-182 AS A BIOMARKER FOR MUSCLE ATROPHY AND THERAPEUTIC APPLICATIONS | EMORY UNIVERSITY (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140255927-A1 | RNA SPLICING ALTERATIONS AND U1 SMALL NUCLEAR RIBONUCLEOPROTEINS IN NEURODEGENERATIVE DISEASES | EMORY UNIVERSITY (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098863-A1 | Tension-Activated Cell Tagging (TaCT) | EPCAM, TIAL1, ANXA2 | HIF1A 2919/4885MAPT 1390/4885PDE4A 4375/4885 |
| US-20260092918-A1 | Molecular Tension Probes and Methods to Determine or Monitor the Efficacy of Cancer and Other Immune Therapies | CD2, CD47, CD4 | HIF1A 1439/4885MAPT 1626/4885PDE4A 4631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.